Pharma Pioneer

Inozyme Pharma Reports Encouraging Preliminary Results from Phase 1/2 INZ-701 Studies in Adults with PXE and ENPP1 Deficiencies

16 May 2024
2 min read

Inozyme Pharma, Inc., a clinical-stage biopharmaceutical company working on novel treatments for rare diseases associated with pathological mineralization and intimal proliferation, recently reported promising data from Phase 1/2 clinical trials of their drug INZ-701. This drug is intended for the treatment of ABCC6 Deficiency and ENPP1 Deficiency, conditions marked by abnormal calcium accumulation in the body.

The trials have shown that INZ-701 is safe and generates positive immunogenic responses. Patients participating in these studies displayed clinical improvements in areas such as cardiovascular health and visual function, along with overall positive patient-reported outcomes.

ABCC6 Deficiency, especially in early-onset forms, commonly leads to critical complications like stroke. The ongoing trials involving INZ-701 have included participants across various dosage groups and have continually monitored effects such as the stabilization of vascular pathology and improvements in visual function, even suggesting that such treatments could be extended to pediatric patients at risk of severe outcomes.

Additionally, data from patients with ENPP1 Deficiency suggest that weekly doses of INZ-701 can effectively maintain beneficial blood markers that correlate with disease progression. These findings support the potential of INZ-701 in regular clinical use and encourage further trials.

Inozyme Pharma plans to further explore INZ-701's applications, particularly aiming to initiate pivotal trials in pediatric patients with ABCC6 Deficiency by early 2025. This decision follows both natural history studies and responses observed in ongoing trials, highlighting the urgent need for effective treatments in preventing severe complications such as stroke and cardiovascular disease in young patients.

The company also shared insights on the safety and efficacy of different dosing schedules, confirming the general tolerance and sustained benefits observed in longer-term treatments involving home administration of the drug.

How to obtain the latest research advancements in the field of biopharmaceuticals?

In the Synapse database, you can keep abreast of the latest research and development advances in drugs, targets, indications, organizations, etc., anywhere and anytime, on a daily or weekly basis. Click on the image below to embark on a brand new journey of drug discovery!

图形用户界面, 文本, 应用程序, 聊天或短信

描述已自动生成

CYP-006TK Clinical Trial for Diabetic Foot Ulcers Completes Patient Recruitment
Pharma Pioneer
2 min read
CYP-006TK Clinical Trial for Diabetic Foot Ulcers Completes Patient Recruitment
16 May 2024
Cynata Therapeutics has successfully completed patient recruitment for its Phase 1 clinical trial of CYP-006TK, a treatment for diabetic foot ulcers (DFU).
Read →
Lead Researcher at City of Hope Presents MT APOLLO Clinical Findings at Global Hematologic Malignancies Summit
Pharma Pioneer
3 min read
Lead Researcher at City of Hope Presents MT APOLLO Clinical Findings at Global Hematologic Malignancies Summit
16 May 2024
The trial focused on MT-601, a novel T cell therapy targeting various tumor antigens, and was well-tolerated by participants, leading to sustained objective responses.
Read →
CytomX Commences Phase 1 Clinical Trial with Patient Dosing of EpCAM-Targeted ADC CX-2051 for Advanced Solid Tumors
Pharma Pioneer
2 min read
CytomX Commences Phase 1 Clinical Trial with Patient Dosing of EpCAM-Targeted ADC CX-2051 for Advanced Solid Tumors
16 May 2024
CytomX Therapeutics has initiated a Phase 1 clinical trial for CX-2051, an antibody drug conjugate (ADC) aimed at treating advanced solid tumors.
Read →
ORYZON Receives FDA Clearance for Iadademstat and Immune Checkpoint Inhibitors Trial in 1L Extensive Stage SCLC
Pharma Pioneer
2 min read
ORYZON Receives FDA Clearance for Iadademstat and Immune Checkpoint Inhibitors Trial in 1L Extensive Stage SCLC
16 May 2024
Oryzon Genomics, a biopharmaceutical firm specializing in epigenetic therapies for diseases with significant medical needs, has received approval from the U.S. FDA to begin a Phase I/II clinical trial.
Read →
Get started for free today!
Accelerate Strategic R&D decision making with Synapse, PatSnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.
Start your data trial now!
Synapse data is also accessible to external entities via APIs or data packages. Empower better decisions with the latest in pharmaceutical intelligence.